These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20414314)

  • 1. Therapy: raising HDL cholesterol levels: a flight of Icarus?
    Rossi GP; Rizzoni D
    Nat Rev Endocrinol; 2010 May; 6(5):245-6. PubMed ID: 20414314
    [No Abstract]   [Full Text] [Related]  

  • 2. Extended-release niacin or ezetimibe and carotid intima-media thickness.
    Taylor AJ; Villines TC; Stanek EJ; Devine PJ; Griffen L; Miller M; Weissman NJ; Turco M
    N Engl J Med; 2009 Nov; 361(22):2113-22. PubMed ID: 19915217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin therapy with ezetimibe or niacin in high-risk patients.
    Kastelein JJ; Bots ML
    N Engl J Med; 2009 Nov; 361(22):2180-3. PubMed ID: 19915218
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of ezetimibe in the prevention of cardiovascular disease: where do we stand after ARBITER 6-HALTS.
    Howard WJ
    Nutr Metab Cardiovasc Dis; 2010 Jun; 20(5):295-300. PubMed ID: 20556890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional assessment of HDL: Moving beyond static measures for risk assessment.
    Rosenson RS
    Cardiovasc Drugs Ther; 2010 Feb; 24(1):71-5. PubMed ID: 20094763
    [No Abstract]   [Full Text] [Related]  

  • 6. The HALTS trial--halting atherosclerosis or halted too early?
    Blumenthal RS; Michos ED
    N Engl J Med; 2009 Nov; 361(22):2178-80. PubMed ID: 19915216
    [No Abstract]   [Full Text] [Related]  

  • 7. HDL and LDL as therapeutic targets for cardiovascular disease prevention: the possible role of niacin.
    Olsson AG
    Nutr Metab Cardiovasc Dis; 2010 Oct; 20(8):553-7. PubMed ID: 20739153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol conundrum.
    Diep F
    Sci Am; 2011 Nov; 305(5):32-3. PubMed ID: 22125858
    [No Abstract]   [Full Text] [Related]  

  • 9. Niacin compared with ezetimibe.
    Duivenvoorden R; Vergeer M; Kastelein JJ
    N Engl J Med; 2010 Mar; 362(11):1046-7; author reply 1048. PubMed ID: 20301795
    [No Abstract]   [Full Text] [Related]  

  • 10. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
    Villines TC; Stanek EJ; Devine PJ; Turco M; Miller M; Weissman NJ; Griffen L; Taylor AJ
    J Am Coll Cardiol; 2010 Jun; 55(24):2721-6. PubMed ID: 20399059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid disorders.
    Kole LA
    JAAPA; 2009 Nov; 22(11):54-5. PubMed ID: 19999177
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
    Fazio S; Guyton JR; Polis AB; Adewale AJ; Tomassini JE; Ryan NW; Tershakovec AM
    Am J Cardiol; 2010 Feb; 105(4):487-94. PubMed ID: 20152243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ezetimibe and recent clinical trials: a look on the bright side.
    Ahmed MH
    Expert Opin Drug Saf; 2010 Jul; 9(4):511-4. PubMed ID: 20377476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDL- cholesterol: a nut too hard to crack?
    Kaski JC
    Cardiovasc Drugs Ther; 2012 Oct; 26(5):433-4. PubMed ID: 22825352
    [No Abstract]   [Full Text] [Related]  

  • 15. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
    Bajnok L
    Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors].
    Broncel M; Balcerak M; Chojnowska-Jezierska J
    Pol Merkur Lekarski; 2007 Jan; 22(127):62-5. PubMed ID: 17477094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia.
    Jelesoff NE; Ballantyne CM; Xydakis AM; Chiou P; Jones PH; Guyton JR
    Endocr Pract; 2006; 12(2):159-64. PubMed ID: 16690463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
    ; Boden WE; Probstfield JL; Anderson T; Chaitman BR; Desvignes-Nickens P; Koprowicz K; McBride R; Teo K; Weintraub W
    N Engl J Med; 2011 Dec; 365(24):2255-67. PubMed ID: 22085343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner.
    Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Ueda Y; Suzuki T; Ueda S; Fukami K; Okuda S; Yamagishi S
    Pharmacol Res; 2010 Jan; 61(1):58-61. PubMed ID: 19666118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ezetimibe in diabetes: more than cholesterol lowering?
    Sarigianni M; Katsiki N; Mikhailidis DP
    Curr Med Res Opin; 2010 Oct; 26(10):2517-20. PubMed ID: 20843163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.